215 related articles for article (PubMed ID: 37601247)
1. MMP12 serves as an immune cell-related marker of disease status and prognosis in lung squamous cell carcinoma.
Zhang W; Li GS; Gan XY; Huang ZG; He RQ; Huang H; Li DM; Tang YL; Tang D; Zou W; Liu J; Dang YW; Chen G; Zhou HF; Kong JL; Lu HP
PeerJ; 2023; 11():e15598. PubMed ID: 37601247
[TBL] [Abstract][Full Text] [Related]
2. Significance of
Lin H; Wang J; Shi Q; Wu M
PeerJ; 2024; 12():e17338. PubMed ID: 38708353
[TBL] [Abstract][Full Text] [Related]
3. SYNJ2 is a novel and potential biomarker for the prediction and treatment of cancers: from lung squamous cell carcinoma to pan-cancer.
Hou W; Li GS; Gao L; Lu HP; Zhou HF; Kong JL; Chen G; Xia S; Wei HY
BMC Med Genomics; 2022 May; 15(1):114. PubMed ID: 35581615
[TBL] [Abstract][Full Text] [Related]
4. M7G-Related lncRNAs predict prognosis and regulate the immune microenvironment in lung squamous cell carcinoma.
Pan J; Huang Z; Lin H; Cheng W; Lai J; Li J
BMC Cancer; 2022 Nov; 22(1):1132. PubMed ID: 36333719
[TBL] [Abstract][Full Text] [Related]
5. Identification of specific prognostic markers for lung squamous cell carcinoma based on tumor progression, immune infiltration, and stem index.
Wu R; Ma R; Duan X; Zhang J; Li K; Yu L; Zhang M; Liu P; Wang C
Front Immunol; 2023; 14():1236444. PubMed ID: 37841237
[TBL] [Abstract][Full Text] [Related]
6. A 13-gene signature to predict the prognosis and immunotherapy responses of lung squamous cell carcinoma.
Yang Q; Gong H; Liu J; Ye M; Zou W; Li H
Sci Rep; 2022 Aug; 12(1):13646. PubMed ID: 35953696
[TBL] [Abstract][Full Text] [Related]
7. Construction of a predictive model for immunotherapy efficacy in lung squamous cell carcinoma based on the degree of tumor-infiltrating immune cells and molecular typing.
Yang L; Wei S; Zhang J; Hu Q; Hu W; Cao M; Zhang L; Wang Y; Wang P; Wang K
J Transl Med; 2022 Aug; 20(1):364. PubMed ID: 35962453
[TBL] [Abstract][Full Text] [Related]
8. Deciphering a cell death-associated signature for predicting prognosis and response to immunotherapy in lung squamous cell carcinoma.
Mao G; Yang D; Liu B; Zhang Y; Ma S; Dai S; Wang G; Tang W; Lu H; Cai S; Zhu J; Yang H
Respir Res; 2023 Jul; 24(1):176. PubMed ID: 37415224
[TBL] [Abstract][Full Text] [Related]
9. Effects of Lipid Metabolism-Related Genes PTGIS and HRASLS on Phenotype, Prognosis, and Tumor Immunity in Lung Squamous Cell Carcinoma.
Lei K; Liang R; Tan B; Li L; Lyu Y; Wang K; Wang W; Wang K; Hu X; Wu D; Lin H; Wang M
Oxid Med Cell Longev; 2023; 2023():6811625. PubMed ID: 36703911
[TBL] [Abstract][Full Text] [Related]
10. Diagnostic Value of GDF10 for the Tumorigenesis and Immune Infiltration in Lung Squamous Cell Carcinoma.
Wang XJ; Chen JP; Qiao XW; Meng WY; Wang YW; Meng YC; Zhao R; Lin W; Liao YD; Xiao H; Mei PY
Curr Med Sci; 2024 Apr; 44(2):309-327. PubMed ID: 38517673
[TBL] [Abstract][Full Text] [Related]
11. Construction of a prognostic model for lung squamous cell carcinoma based on immune-related genes.
Pu J; Teng Z; Yang W; Zhu P; Zhang T; Zhang D; Wang B; Hu Z; Song Q
Carcinogenesis; 2023 May; 44(2):143-152. PubMed ID: 36455238
[TBL] [Abstract][Full Text] [Related]
12. The Expression and Survival Significance of FOXD1 in Lung Squamous Cell Carcinoma: A Meta-Analysis, Immunohistochemistry Validation, and Bioinformatics Analysis.
Xie F; Li Y; Liang B
Biomed Res Int; 2022; 2022():7798654. PubMed ID: 35607308
[TBL] [Abstract][Full Text] [Related]
13. Downregulation of T-cell cytotoxic marker IL18R1 promotes cancer proliferation and migration and is associated with dismal prognosis and immunity in lung squamous cell carcinoma.
Guo Q; Wu CY; Jiang N; Tong S; Wan JH; Xiao XY; Mei PY; Liu HS; Wang SH
Front Immunol; 2022; 13():986447. PubMed ID: 36544782
[TBL] [Abstract][Full Text] [Related]
14. Cancer Stemness-Based Prognostic Immune-Related Gene Signatures in Lung Adenocarcinoma and Lung Squamous Cell Carcinoma.
Li N; Li Y; Zheng P; Zhan X
Front Endocrinol (Lausanne); 2021; 12():755805. PubMed ID: 34745015
[TBL] [Abstract][Full Text] [Related]
15. DNA damage repair gene signature model for predicting prognosis and chemotherapy outcomes in lung squamous cell carcinoma.
Wang X; Huang Z; Li L; Wang G; Dong L; Li Q; Yuan J; Li Y
BMC Cancer; 2022 Aug; 22(1):866. PubMed ID: 35941578
[TBL] [Abstract][Full Text] [Related]
16. Identification of Immune-Related Gene Signatures in Lung Adenocarcinoma and Lung Squamous Cell Carcinoma.
Li N; Wang J; Zhan X
Front Immunol; 2021; 12():752643. PubMed ID: 34887858
[TBL] [Abstract][Full Text] [Related]
17. Identification of Clinical Prognostic Regulators and Analysis of Ferroptosis-Related Signatures in the Tumor Immune Microenvironment in Lung Squamous Cell Carcinoma.
Wang W; Cui G; Zhao S
Dis Markers; 2023; 2023():9155944. PubMed ID: 36845013
[TBL] [Abstract][Full Text] [Related]
18. A robust signature associated with patient prognosis and tumor immune microenvironment based on immune-related genes in lung squamous cell carcinoma.
Zhou H; Zhang H; Shi M; Wang J; Huang Z; Shi J
Int Immunopharmacol; 2020 Nov; 88():106856. PubMed ID: 32777677
[TBL] [Abstract][Full Text] [Related]
19. A novel pyroptosis-related lncRNA prognostic signature associated with the immune microenvironment in lung squamous cell carcinoma.
Zhou W; Zhang W
BMC Cancer; 2022 Jun; 22(1):694. PubMed ID: 35739504
[TBL] [Abstract][Full Text] [Related]
20. MMP12 is a Potential Predictive and Prognostic Biomarker of Various Cancers Including Lung Adenocarcinoma.
Li GS; Tang YX; Zhang W; Li JD; Huang HQ; Liu J; Fu ZW; He RQ; Kong JL; Zhou HF; Chen G
Cancer Control; 2024; 31():10732748241235468. PubMed ID: 38410859
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
